These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7372555)

  • 1. Correlation of agar-disc-diffusion tests with minimum inhibitory concentrations of cefonicid (SK&F 75073) and cephalothin.
    Grappel SF; Guarini JR; Actor P; Weisbach JA
    J Antibiot (Tokyo); 1980 Jan; 33(1):85-7. PubMed ID: 7372555
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluation of the cefonicid disk test criteria, including disk quality control guidelines.
    Barry AL; Jones RN; Thornsberry C
    J Clin Microbiol; 1983 Feb; 17(2):232-9. PubMed ID: 6601113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefonicid: a stable beta-lactamase inhibitor.
    Mehta RJ; Newman DJ; Bowie BA; Nash CH; Actor P
    J Antibiot (Tokyo); 1981 Feb; 34(2):202-5. PubMed ID: 6975269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefonicid, a long acting cephalosporin: in vitro activity compared with three cephalosporins and gentamicin.
    Hamilton-Miller JM; Patel R; Brumfitt W
    Drugs Exp Clin Res; 1986; 12(11):861-9. PubMed ID: 3816503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in-vitro activity of cefamandole, cefoxitin, cefuroxime and cephalothin.
    Brorson JE; Norrby R
    Scand J Infect Dis Suppl; 1978; (13):88-93. PubMed ID: 278150
    [No Abstract]   [Full Text] [Related]  

  • 6. A multicentre study of the susceptibility of a variety of bacteria to cephalothin, cefamandole, tobramycin and gentamicin.
    du T Naudé W; van den Ende J; Botha P; Forder A; Hyland J; de Klerk HC; Neiteler BF; Koornhof HJ; Robinson R; Robins-Browne R; Block C; Appelbaum PC; Africa CW; van Rensburg AJ; Jooste PJ; Crewe-Browne H; Fernandez A
    S Afr Med J; 1977 Nov; 52(20):798-800. PubMed ID: 305120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro sensitivity of hospital-isolated pathogenic bacterial strains to 4 different cephalosporins: cephaloridine, cefotaxime, cefoxitin, cefonicid].
    Rosina M; Mauri J; Germiniani R; Mastropasqua E; Figini G
    Minerva Chir; 1986 Aug; 41(15-16):1347-51. PubMed ID: 3774182
    [No Abstract]   [Full Text] [Related]  

  • 8. In-vitro activities of cefamandole and cephalothin against 1,881 clinical isolates. A multi-center study.
    Barry AL; Schoenknect FD; Shadomy S; Sherris JC; Thornsberry C; Washington JA; Kammer RB
    Am J Clin Pathol; 1979 Nov; 72(5):858-60. PubMed ID: 506998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of cefonicid with other beta-lactams regarding the effect of human and mouse sera on antibacterial activity.
    Uri JV
    Acta Microbiol Hung; 1987; 34(1):39-44. PubMed ID: 3630630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interpretive criteria for cefamandole and cephalothin disk diffusion susceptibility tests.
    Barry AL; Schoenknecht FD; Shadomy S; Sherris JC; Thornsberry C; Washington JA; Kammer RB
    Antimicrob Agents Chemother; 1979 Jan; 15(1):140-1. PubMed ID: 106770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro experience with cefonicid.
    Actor P
    Rev Infect Dis; 1984; 6 Suppl 4():S783-90. PubMed ID: 6522920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaerobic bacteria: evaluation of disc susceptibility to four cephalosporins.
    Dubois J; Pechère JC
    Infection; 1978; 6(6):266-70. PubMed ID: 730395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial activity of five cephalosporins.
    Mutton KJ; Harkness JL
    Pathology; 1981 Jan; 13(1):73-7. PubMed ID: 6784093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefuroxime, cefamandole, cefoxitin, and cephalothin in vitro susceptibility tests: reassessment of the "class representative" concept, confirmation of disk interpretive criteria, and proposed quality control guidelines.
    Barry AL; Jones RN; Thornsberry C
    Am J Clin Pathol; 1983 Aug; 80(2):182-9. PubMed ID: 6881092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paradoxical susceptibility to cephalothin and cefamandole of a Klebsiella pneumoniae isolate producing extended-spectrum beta-lactamase (TEM-3).
    Gaillot O; Mallea M; Philippon A; Pages JM; Simonet M
    J Antimicrob Chemother; 1996 Jan; 37(1):194-6. PubMed ID: 8647766
    [No Abstract]   [Full Text] [Related]  

  • 16. Review of the new second-generation cephalosporins: cefonicid, ceforanide, and cefuroxime.
    Tartaglione TA; Polk RE
    Drug Intell Clin Pharm; 1985 Mar; 19(3):188-98. PubMed ID: 3884304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity and clinical pharmacology of cefamandole in comparison to cephalothin.
    Simon VC; Malerczyk V; Nixdorf F
    J Antimicrob Chemother; 1978 Jan; 4(1):85-90. PubMed ID: 624694
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of Escherichia coli susceptibility to cephalothin, cefazolin, ceforanide, and cefamandole.
    Greenberg RN; Bollinger M
    Clin Ther; 1985; 7(2):151-3. PubMed ID: 3886140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cooperative study of bacterial incidence and susceptibility to cefamandole and other antibiotics (author's transl)].
    de Vega JC; Pais JR; del Tánago AG
    Med Clin (Barc); 1980 May; 74(10):387-94. PubMed ID: 7412431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro bactericidal activity of cefonicid, ceftizoxime, and penicillin against group B streptococci.
    Bayer AS; Morrison JO; Kim KS
    Antimicrob Agents Chemother; 1982 Feb; 21(2):344-6. PubMed ID: 6280602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.